Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region

Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region

Abstract Background With emerging evidence on the efficacy of adding dapagliflozin to standard care for patients with heart failure with reduced ejection fraction (HFrEF), this study assessed the cost-effectiveness of add-on dapagliflozin to standard care versus standard care alone for HFrEF from th...

Full description

Bibliographic Details
Main Authors: Chia-Te Liao, Chun-Ting Yang, Han Siong Toh, Wei-Ting Chang, Hung-Yu Chang, Fang-Hsiu Kuo, Mei-Chuan Lee, Yi-Ming Hua, Hsin-Ju Tang, Carol Strong, Huang-Tz Ou
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Cardiovascular Diabetology
Subjects:
Heart failure
Dapagliflozin
Cost-effectiveness
Online Access:https://doi.org/10.1186/s12933-021-01387-3

Internet

https://doi.org/10.1186/s12933-021-01387-3

Similar Items